Skip to main content

Effects of Cannabis Use in Stage III-IV Non-small Cell Lung Cancer Patients

Trial Status: Active

This trial studies the effects of cannabis use on stage III-IV non-small cell lung cancer patients undergoing treatment for their cancer. Studying the effects of different types of cannabis and cannabinoids (the different constituent parts of cannabis) on cancer-related symptoms, quality of life, and cognition when used by patients undergoing treatment for cancer, may help doctors inform patient choices and future harm reduction efforts.

Inclusion Criteria

  • Provision to sign and date the consent form
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Have a diagnosis of stage III-IV non-small cell lung cancer (NSCLC) or other comparable tumor types
  • Have intent to use Cannabis to treat their symptoms

Exclusion Criteria

  • Report of other non-prescription drug use, such as cocaine, heroin, methamphetamine in the past 60 days
  • Actively seeking or in treatment for any substance use disorder
  • Acute illness other than cancer that could affect cognition or compliance per the decision of the study Doctor of Medicine (M.D.)
  • Premenopausal females who are pregnant or trying to become pregnant. Participants who become pregnant while participating in the study will also no longer be eligible for participation
  • A Telephone Interview for Cognitive Status (TICS) score indicating moderate or severe cognitive impairment at screening


University of Colorado Hospital
Status: ACTIVE
Contact: Angela Bryan
Phone: 303-492-8264
University of Colorado – Boulder
Status: ACTIVE
Contact: Angela Bryan
Phone: 303-492-8264


I. To demonstrate the number of contacts necessary to enroll 30 eligible patients and demonstrate reasonable compliance with study procedures within six months of active recruiting.


Patients use their marijuana (cannabis) product of choice orally (PO) for 2 weeks then undergo blood collection and complete questionnaires, memory and thinking assessments at baseline then at 1 and 2 hours after each cannabis use.

After completion of study, patients are followed up at 1 month.

Trial Phase Phase NA

Trial Type Observational

Lead Organization
University of Colorado Hospital

Principal Investigator
Angela Bryan

  • Primary ID 18-0836
  • Secondary IDs NCI-2020-01067
  • ID NCT03617692